Why the study?
Smokers typically struggle to quit on their own, requiring tailored cessation strategies, particularly for those with cardiovascular and psychiatric comorbidities.
This review summarizes the neurobiology of nicotine addiction and withdrawal, alongside current pharmacological strategies for smoking cessation to aid in cardiovascular prevention.
Answers are grounded in this paper and cite their sources.
Smoking cessation reduces CV mortality; leaves open optimal strategies for nicotine dependence treatment.
The biggest preventable cause of disease and mortality globally is tobacco smoking, which is one of the main public health issues.The mortality rate and subsequent cardiovascular events are decreased by quitting smoking.Smoking is a true chronic illness marked by the emergence of a dependency state brought on mostly by nicotine.Because of this problem, smokers typically find it impossible to stop smoking on their own.Treatment options for smoking dependence range from non-pharmacological to pharmaceutical therapy.Currently, it is well acknowledged that smoking cessation medications work well and are secure in everyday situations.The therapist should tailor the smoking cessation strategy based on the most recent scientific data and the patient's preferences, giving particular attention to those patients who have certain cardiovascular and psychiatric comorbidities.Each of these medications has unique properties.The current document aims to provide useful practical guidance to all physicians, particularly those involved in cardiovascular prevention, by summarising the current effective pharmacological strategies for quitting smoking and discussing the contentious issue regarding the use of alternative tobacco products.
No takes yet. Share an insight, caveat, or question.
A 2023 study conducted a review in Tobacco dependence and nicotine withdrawal syndrome. Pharmacological smoking cessation therapies was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: